Armstrong, A. J., Clarke, N., Oya, M., Procopio, G., de Menezes, J., Guedes, J. D., … Saad, F. (2024). Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. European Urology Oncology, 7(2), 292–296. https://doi.org/10.1016/j.euo.2023.10.004

Armstrong, Andrew J., Noel Clarke, Mototsugu Oya, Giuseppe Procopio, Juliana de Menezes, João Daniel Guedes, Pooja Ghatalia, et al. “Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.” European Urology Oncology 7, no. 2 (April 2024): 292–96. https://doi.org/10.1016/j.euo.2023.10.004.

Armstrong AJ, Clarke N, Oya M, Procopio G, de Menezes J, Guedes JD, et al. Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. European Urology Oncology. 2024 Apr;7(2):292–6.

Armstrong, Andrew J., et al. “Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.” European Urology Oncology, vol. 7, no. 2, Elsevier BV, Apr. 2024, pp. 292–96. Crossref, doi:10.1016/j.euo.2023.10.004.

Armstrong AJ, Clarke N, Oya M, Procopio G, de Menezes J, Guedes JD, Ghatalia P, Nolè F, Din O, Spiegelhalder P, Mincik I, van Alphen R, Lumen N, Hosius C, Zhou D, Barker L, Dujka M, Saad F. Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. European Urology Oncology. Elsevier BV; 2024 Apr;7(2):292–296.